COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial
Status:
Recruiting
Trial end date:
2020-08-23
Target enrollment:
Participant gender:
Summary
Patients with mild and severe coronavirus disease 2019 (COVID 19) will be randomized 3:1:1:3
into four groups: colchicine, ruxolitinib, secukinumab, and control groups. Patients will get
investigated therapy for 10 days. Patients will be follow-up during 45 days after
randomization. Change in clinical assessment score COVID 19 (CAS COVID 19) between baseline
and 12th day will be evaluated as the primary endpoint. Risk of death or mechanical
ventilation during 45 days after randomization will also be assessed
Phase:
Phase 2
Details
Lead Sponsor:
Lomonosov Moscow State University Medical Research and Educational Center